The CDE Approved IND Application To Investigate Combination Of Asieris’ APL-1202 And BeiGene’s Tislelizumab As Neoadjuvant Therapy For MIBC Patients

https://www.thestreet.com/press-releases/the-cde-approved-ind-application-to-investigate-combination-of-asieris-apl-1202-and-beigene-s-tislelizumab-as-neoadjuvant-therapy-for-mibc-patients-15797490
SHANGHAI, Oct. 13, 2021 /PRNewswire/ — Asieris Pharmaceuticals (Asieris) today announced that the Center for Drug Evaluation (CDE) NMPA has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy in patients with …